REG - Solvonis Therapeutic - Notice of Annual General Meeting

Solvonis TherapeuticsAnnouncement

03/06/2025 16:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250603:nRSC2395La&default-theme=true

RNS Number : 2395L  Solvonis Therapeutics PLC  03 June 2025

3 June 2025
Solvonis Therapeutics plc

("Solvonis" or the "Company")

Notice of Annual General Meeting (the "AGM")

 

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical
company focused on developing innovative medicines for the treatment of
addiction and mental health disorders, is pleased to announce that the notice
of the Company's 2025 AGM and proxy form have today been posted to
shareholders and can be found on the Company's website
at https://solvonis.com/investor-relations/shareholder-circulars
(https://solvonis.com/investor-relations/shareholder-circulars) .

The Annual General Meeting will take place at 12.00 noon on 27 June 2025 at
the Company's registered office being, 25 Eccleston Place, London SW1W 9NF.

In compliance with Listing Rule 9.6.1R, the notice of AGM and proxy form have
today been submitted to the National Storage Mechanism and will shortly be
available at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

Enquiries:

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

anthony@solvonis.com

Allenby Capital Limited (Financial Adviser and Joint Broker)

Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)

Guy McDougall (Sales & Corporate Broking)

+44 (0) 20 3328 5656

Singer Capital Markets (Joint Broker)

Phil Davies

+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders.
Headquartered in London and listed on the main market of the London Stock
Exchange, Solvonis is advancing a differentiated pipeline of repurposed and
novel compounds that target high-burden neuropsychiatric conditions with
significant unmet need.

 

The company's lead programs address Alcohol Use Disorder (AUD) and
Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million
people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in
Phase 3 trials for severe AUD in Europe and the UK. SVN-002 is preparing for a
Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a
preclinical PTSD program leveraging novel serotonin-dopamine modulators
designed to enhance pro-social behaviour and long-term outcomes.

 

With a capital-efficient model, dual development strategy, and near-term
partnering opportunities, Solvonis is positioned to generate value through
innovation in neuropsychiatry.

www.solvonis.com (http://www.solvonis.com) | LinkedIn
(http://www.linkedin.com/company/solvonis) | X (formerly Twitter)
(https://x.com/SolvonisTx)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAPKNBNKBKDOAK